Vollmar, Angelika - Ludwig-Maximilians-Universität München

个人简介

1977 - 1981 Pharmaceutical training at the Ludwig-Maximilians-University of Munich (LMU) 1982 Approbation 1982 - 1984 Graduate School - Dr. rer. nat. at the Institute of Pharmaceutical Biology(Prof. Dr. H. Wagner), LMU 1985 - 1987 Post-doc- DFG-fellowship at the Department of Biochemistry,University of California, Los Angeles, USA (Prof. Dr. H. Herschman) 1991 Habilitation (Dr. med. vet. habil.) in Pharmacology, Toxicology and Pharmacy Professional career Year Occupation 1991 "Privatdozentin" for Clinical Pharmacology and Pharmacy, Veterinary School, LMU 1991 Invitated Researcher at the Laboratory of Molecular Genetics, Clinical Research Institute of Montreal, Canada (Prof. Dr. M. Nemer) 1991 - 1994 Group leader (C2) at the Institute of Pharmacology, Toxicology and Pharmacy, Veterinary School, LMU 1993 Call for C3- Professorship "Pharmaceutical Biochemistry" at the University of Heidelberg 1994 Professorship (C3) for "Arzneiverordnungs- und Arzneianfertigungslehre", Veterinary School, LMU 1998 Professorship and Chair (C4) of "Pharmaceutical Biology" Department of Pharmacy, LMU Functions / Honors Year Function / Honor 1998 Phoenix Pharmacy Award 1998 - 2011 Editorial Board Member: Planta Medica, Phytomedicine 2000 - 2002 Director of the Department of Pharmacy, LMU 2001 - 2005 Member of the "Deutschen Arzneibuch-Kommission" 2001 - 2008 Board Member of the "Dr. August und Dr. Anni Lesmüller Stiftung" 2003 - 2011 Tutor ("Vertrauensdozentin") of the Cusanuswerk 2004 - 2007 "Fachkollegiatin" of the German Research Counsil (DFG) (Section Medicine) 2006 - 2011 Consultant of the "Deutsche Bischofskonferenz" (Commission for Science and Culture) since 2007 Member of the Scientific Advisory Board of the Catholic Academy of Bavaria 2007 - 2010 Mentor of the LMUexcellent Program 2009 Therese-von-Bayern-Award since 2009 Speaker of the Scientific Advisory Board of the "Robert-Bosch-Stiftung" since 2010 Board Member of the "Dr. Mildred Scheel Stiftung für Krebsforschung" 2010 - 2013 Mentor for the Helmholtz-Academy since 2010 Speaker of the DFG-Research Group 1406 since 2011 Board Member of the "Goethe Graduate Academy (GRADE)" since 2011 Member of the Center for Advanced Studies (CASLMU) since 2011 Member of the NIM (Nanosystems Initiative Munich) Excellence Cluster 2011 Bundesverdienstkreuz am Bande 2012 Memory Medal of Palacky University, Olomouc,CZ 2006 - 2012 Member of the "Senatskommission für Klinische Forschung" of the DFG 2007 - 2013 Member of the "Hauptausschuss" and "Senat" of the DFG 2012 - 2014 Director of the Department of Pharmacy since 2014 Member of the Scientific Advisory Board of DECHEMA ("Small Molecule Natural Compounds with Biological Activity") since 2014 Member of the Scientific Advisory Board of DECHEMA ("Medicinal Biotechnology") since 2014 Member of the Scientific Advisory Board of the "Helmholtz - Zentrum für Infektionsforschung (HZI)"

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - a novel therapeutic approach. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. J Hepatol. 2015 Feb 4. pii: S0168-8278(15)00062-8. doi: 10.1016/j.jhep.2015.01.031. [Epub ahead of print] PMID: 25660209. Select item 25391145 The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. Menhofer MH, Kubisch R, Schreiner L, Zorn M, Foerster F, Mueller R, Raedler JO, Wagner E, Vollmar AM, Zahler S. PLoS One. 2014 Nov 12;9(11):e112542. doi: 10.1371/journal.pone.0112542. eCollection 2014. Select item 25256790 A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells. Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, Fulda S, Zahler S, Antes I, Kazmaier U, Sieber SA, Vollmar AM. Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12960-5. doi: 10.1002/anie.201406577. Epub 2014 Sep 26. PMID: 25256790. Select item 25239826 In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor. Menhofer MH, Bartel D, Liebl J, Kubisch R, Busse J, Wagner E, Müller R, Vollmar AM, Zahler S. Cardiovasc Res. 2014 Nov 1;104(2):303-14. doi: 10.1093/cvr/cvu210. Epub 2014 Sep 19. PMID: 25239826. Select item 25165884 Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ. Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, Schmoeckel E, Mayr D, Schmitt S, Huettel S, Zischka H, Mueller R, Vollmar AM. Cell Death Dis. 2014 Aug 28;5:e1398. doi: 10.1038/cddis.2014.363. PMID: 25165884. Select item 25069048 The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. Braig S, Bischoff F, Abhari BA, Meijer L, Fulda S, Skaltsounis L, Vollmar AM. Biochem Pharmacol. 2014 Sep 15;91(2):157-67. doi: 10.1016/j.bcp.2014.07.009. Epub 2014 Jul 25. PMID: 25069048. Select item 24679674 Pharmacological characterization of actin-binding (-)-doliculide. Foerster F, Braig S, Chen T, Altmann KH, Vollmar AM. Bioorg Med Chem. 2014 Sep 15;22(18):5117-22. doi: 10.1016/j.bmc.2014.03.003. Epub 2014 Mar 15. PMID: 24679674. Select item 24482380 V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, Vollmar AM. Mol Cancer Ther. 2014 Apr;13(4):926-37. doi: 10.1158/1535-7163.MCT-13-0484. Epub 2014 Jan 30. PMID: 24482380. Select item 24437936 Simplified pretubulysin derivatives and their biological effects on cancer cells. Kubisch R, von Gamm M, Braig S, Ullrich A, Burkhart JL, Colling L, Hermann J, Scherer O, Müller R, Werz O, Kazmaier U, Vollmar AM. J Nat Prod. 2014 Mar 28;77(3):536-42. doi: 10.1021/np4008014. Epub 2014 Jan 17. PMID: 24437936. Select item 24434509 Pretubulysin: a new option for the treatment of metastatic cancer. Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM. Cell Death Dis. 2014 Jan 16;5:e1001. doi: 10.1038/cddis.2013.510. Select item 24371121 A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation. Hornburger MC, Mayer BA, Leonhardt S, Willer EA, Zahler S, Beyerle A, Rajalingam K, Vollmar AM, Fürst R. FASEB J. 2014 Apr;28(4):1938-46. doi: 10.1096/fj.13-235754. Epub 2013 Dec 26. PMID: 24371121. Select item 24285578 Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo. Kretzschmann VK, Gellrich D, Ullrich A, Zahler S, Vollmar AM, Kazmaier U, Fürst R. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):294-303. doi: 10.1161/ATVBAHA.113.302155. Epub 2013 Nov 27. Select item 24254321 Regulation of endothelial signaling and migration by v-ATPase. Rath S, Liebl J, Fürst R, Vollmar AM, Zahler S. Angiogenesis. 2014 Jul;17(3):587-601. doi: 10.1007/s10456-013-9408-z. Epub 2013 Nov 20. PMID: 24254321. Select item 24166050 V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E. Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14. PMID: 24166050. Select item 24055142 V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM. Mol Oncol. 2014 Feb;8(1):9-19. doi: 10.1016/j.molonc.2013.08.011. Epub 2013 Sep 5. PMID: 24055142. Select item 23972628 Determination of the prevalence of whole blood taurine in Irish wolfhound dogs with and without echocardiographic evidence of dilated cardiomyopathy. Vollmar AC, Fox PR, Servet E, Biourge V. J Vet Cardiol. 2013 Sep;15(3):189-96. doi: 10.1016/j.jvc.2013.03.005. Epub 2013 Aug 22. PMID: 23972628. Select item 23946383 Indirubin derivative 6BIO suppresses metastasis. Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L, Vollmar AM. Cancer Res. 2013 Oct 1;73(19):6004-12. doi: 10.1158/0008-5472.CAN-12-4358. Epub 2013 Aug 14. Select item 23923626 A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment. Fürst R, Vollmar AM. Pharmazie. 2013 Jul;68(7):478-83. Review. PMID: 23923626. Select item 23336010 Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. Weitensteiner SB, Liebl J, Krystof V, Havlíček L, Gucký T, Strnad M, Fürst R, Vollmar AM, Zahler S. PLoS One. 2013;8(1):e54607. doi: 10.1371/journal.pone.0054607. Epub 2013 Jan 15. Select item 23168408 Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, Efferth T, Trauner D, Vollmar AM. J Biol Chem. 2013 Jan 11;288(2):1385-96. doi: 10.1074/jbc.M112.412007. Epub 2012 Nov 20.